Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 184 of 5804
-
Ancient herbal formula put to the test against diabetic kidney disease
Disease control Not yet recruitingDiabetic nephropathy (DN) is a leading cause of end-stage kidney disease worldwide and is associated with a high risk of cardiovascular events and mortality. Despite current standard therapies including renin-angiotensin system inhibitors (ACEI/ARB), glycemic control, and blood p…
Phase: PHASE4 • Sponsor: Chen Xiangmei • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could a pill plus walking ease knee pain and lift mood in veterans?
Symptom relief Not yet recruitingKnee osteoarthritis (KOA) is one of the most common causes of chronic pain, mobility problems, and disability among United States Veterans. Many Veterans with KOA also experience depressive symptoms, which can worsen pain, reduce motivation to exercise, and make recovery more dif…
Phase: PHASE2 • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New Two-Step surgery could spare High-Risk women from early menopause
Prevention Not yet recruiting• FIMBRIMENOP-2402 study aims to evaluate the long-term management of cancer risks in premenopausal women who have a genetic predisposition to tubo-ovarian or primary peritoneal carcinoma, such as mutations in BRCA1, BRCA2, RAD51C, RAD51D, or PALB2 genes. This study offers an alt…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Prevention
Last updated Jun 27, 2026 11:02 UTC
-
Experimental cell therapy takes on Drug-Resistant melanoma
Disease control Not yet recruitingThe protocol is a Simon's 2-stage, non-randomized, open label, multi-site, phase 2 trial for patients with advanced metastatic, recurrent and unresectable malignant melanoma that has recurred or relapsed after prior anti-PD-(L)1 therapy.
Phase: PHASE2 • Sponsor: Rapa Therapeutics LLC • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Heart attack without blockage: trial tests gentler blood thinners for SCAD
Disease control Not yet recruitingSpontaneous coronary artery dissection (SCAD) is a rare cause of acute coronary syndrome in which blood flow to the heart muscle is reduced or interrupted. It predominantly affects women between 30 and 55 years of age and typically occurs in the absence of atherosclerosis. For ma…
Phase: PHASE4 • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug duo aims to shrink tough head and neck tumors
Disease control Not yet recruitingThe goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer.
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for young AML patients: targeted drug combo tested in phase 2 trial
Disease control Recruiting nowThis phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute myeloid leukemia (CBF-AML). Venetoclax is in a class of m…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
A urine test may boost HIV prevention — a trial puts it to the test
Disease control Not yet recruitingThe goal of this randomized trial study is to learn if drug-level feedback counseling works to improve oral PrEP adherence in adolescent girls and young women. Researchers will compare urine TFV assay positivity between arms. All participants will attend visits on the same sched…
Phase: NA • Sponsor: University of Washington • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New combo attack on kidney cancer: radiation plus two drugs
Disease control Not yet recruitingTo investigate the objective response rate (ORR) of stereotactic body radiotherapy (SBRT) combined with anlotinib and beromuzumab in locally advanced/metastatic renal cell carcinoma.
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New study brings HIV prevention and treatment to the Driver's seat
Prevention Not yet recruitingLong-acting injectable antiretroviral therapy (LAI ART) and Pre-Exposure Prophylaxis (LAI PrEP) have the potential to transform HIV treatment and prevention, especially in reaching individuals such as commercial minibus drivers who have minimal or no contact with traditional heal…
Phase: PHASE4 • Sponsor: George Washington University • Aim: Prevention
Last updated Jun 27, 2026 12:32 UTC
-
AI scans and blood tests could predict who responds to stomach cancer chemotherapy
Knowledge-focused Not yet recruitingThis prospective cohort study aims to construct an artificial intelligence (AI)-derived predictive model for neoadjuvant chemotherapy response prediction in patients with locally advanced gastric cancer based on preoperative ultrasound (US), computed tomography (CT) images and li…
Sponsor: Liu Yang • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Can a phone app stop suicidal thoughts? new trial aims to find out.
Symptom relief Not yet recruitingThis study aims to evaluate the acceptability, safety, and efficacy of a smartphone-delivered intervention called Therapeutic Evaluative Conditioning for Suicide (TEC-S) in reducing suicidal thoughts and behaviors (STB) among adults with recent and frequent suicide ideation.
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Blood filter aims to suck cancer cells out of patients with advanced tumors
Disease control Not yet recruitingThis study is a Prospective Single Arm, dual cohort Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal blood purification (EBP) procedure in either mPDAC or mCRC refractory to systemic therapy. Site selection will be depen…
Phase: NA • Sponsor: ExThera Medical Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug aims to shrink rare adrenal tumors
Disease control Not yet recruitingThis study is to examine the effects of oral daily zanzalintinib in participants with unresectable, progressive metastatic pheochromocytoma or paraganglioma.
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
Disease control Not yet recruitingTo learn if the experimental drug S-531011 plus RadScopalTM radiation therapy can help to control previously treated metastatic colorectal cancer.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for head and neck cancer: which drug works best with radiation?
Disease control Not yet recruitingThis phase III trial compares cetuxumab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer who are unable to receive cisplatin. Cetuximab is in a class of medications called monoclonal an…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Quarter-Sized implant could free type 1 diabetes patients from daily insulin
Disease control Not yet recruitingThis study will evaluate the safety and performance of ENCRT-103-hPI, which is a cargo of primary islets inside Encellin's ENC-103-CED. The 103 offers a soft pillow-like encasing to contain and protect the cells from the immune system. The product is implanted in the upper arm or…
Phase: PHASE1 • Sponsor: Encellin • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug could shorten hospital stays for rare drug reaction
Disease control Not yet recruitingDrug Reaction with eosinophilia and Systemic Symptoms (DRESS) is a rare and severe multiorgan drug reaction whose pathophysiological mechanisms underlying remain unclear, but may involve the role of several immune cells like eosinophils. iIndeed,the number of eosinophils is incre…
Phase: PHASE2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktails aim to outsmart Hard-to-Treat T-Cell lymphomas
Disease control Not yet recruitingThis phase I trial tests the safety, side effects and best dose of azacitidine in combination with belinostat and how well the combination works in treating patients with follicular helper T cell lymphoma (TFH) that has come back after a period of improvement (relapsed) or that h…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could a shingles vaccine help fight deadly brain cancer?
Disease control Not yet recruitingIn modern practice a trimodality treatment has emerged as standard of care for histologically confirmed glioblastoma. We hypothesize that the additional vaccination against herpes zoster, after surgical resection followed by irradiation therapy and chemotherapy of patients with …
Phase: PHASE4 • Sponsor: University Hospital, Essen • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC